Beck et al.251 combined long-lasting mRNA-encoded IL-2 with tumor-targeting mAb therapy, thereby inducing a highly pro-inflammatory TME and overcoming tumor resistance resulting from the absence of MHC I. This evidence concerns the gene IL2 and neoplasm.